Filer	Title/Relationship	Filing Date	Planned Shares	Est. Value
Shlevin Harold H.	Director	2026-06-29	22K shares	$112K
Jamil Khurram	Officer	2026-06-26	68K shares	$341K
Shlevin Harold H.	DIRECTOR	2026-06-26	8K shares	$39K
Jamil Khurram	Officer	2026-06-23	8K shares	$26K

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding GALECTIN THERAPEUTICS INC (GALT)?

Major stakeholders currently include Vanguard Capital Management LLC ($5.5M), Marshall Wace, LLP ($3.4M), Osaic Holdings, INC. ($3.1M). Based on the latest 13F filings, there are a total of 100 tracked investment funds and institutions maintaining positions in GALT.

What is the overall institutional sentiment toward GALT recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $8.2M, driven by 50 managers accumulating shares while 40 reduced their exposure.

Which institutions have been selling or reducing their GALT positions?

In the latest period, 24 funds trimmed their holdings, and 16 managers completely exited their positions. The aggregate reported sell value was $11.4M.

Are there any notable investors adding GALT to their portfolios?

Yes, buying activity remains notable. 17 institutions opened new positions in {ticker}, and 33 existing holders added to their shares. The total reported buy value for the quarter amounted to $30.1M.